{"id":5072,"date":"2017-08-22T12:17:11","date_gmt":"2017-08-22T11:17:11","guid":{"rendered":"http:\/\/backup.altanalaw.com\/?p=5072"},"modified":"2017-08-22T12:28:23","modified_gmt":"2017-08-22T11:28:23","slug":"altana-conseille-onxeo-dans-la-cession-a-vectans-pharma-de-deux-produits-non-strategiques-dans-les-pathologies-buccales","status":"publish","type":"post","link":"https:\/\/backup.altanalaw.com\/ja\/medias\/altana-conseille-onxeo-dans-la-cession-a-vectans-pharma-de-deux-produits-non-strategiques-dans-les-pathologies-buccales","title":{"rendered":"Altana conseille Onxeo dans la cession \u00e0 Vectans Pharma de deux produits  non strat\u00e9giques dans les pathologies buccales"},"content":{"rendered":"<p class=\"qtranxs-available-languages-message qtranxs-available-languages-message-ja\">\u7533\u3057\u8a33\u3042\u308a\u307e\u305b\u3093\u3001\u3053\u306e\u30b3\u30f3\u30c6\u30f3\u30c4\u306f\u305f\u3060\u4eca\u3000<a href=\"https:\/\/backup.altanalaw.com\/fr\/wp-json\/wp\/v2\/posts\/5072\" class=\"qtranxs-available-language-link qtranxs-available-language-link-fr\" title=\"Fran\u00e7ais\">Fran\u00e7ais<\/a>\u3068 <a href=\"https:\/\/backup.altanalaw.com\/en\/wp-json\/wp\/v2\/posts\/5072\" class=\"qtranxs-available-language-link qtranxs-available-language-link-en\" title=\"English\">English<\/a>\u3000\u306e\u307f\u3067\u3059\u3002 For the sake of viewer convenience, the content is shown below in this site default language. You may click one of the links to switch the site language to another available language.<\/p><p>Paris, le 22 ao\u00fbt 2017<\/p>\n<p>Altana a conseill\u00e9 le laboratoire de biotechnologies Onxeo cot\u00e9 sur Euronext Paris et le Nasdaq de Copenhague &#8211; sp\u00e9cialis\u00e9 dans le d\u00e9veloppement de m\u00e9dicaments innovants pour le traitement des maladies orphelines &#8211; dans le cadre de la cession de deux produits historiques\u00a0: Sitavig\u00ae (herp\u00e8s labial) et Loramyc\u00ae (candidose oropharyng\u00e9e), au laboratoire priv\u00e9 Vectans Pharma qui d\u00e9veloppe et commercialise des th\u00e9rapies pour les pathologies buccales.<\/p>\n<p>Sitavig\u00ae et Loramyc\u00ae sont les deux premiers produits d\u00e9velopp\u00e9s et enregistr\u00e9s en Europe et aux Etats-Unis par les \u00e9quipes R&amp;D d&#8217;Onxeo. Ils sont actuellement exploit\u00e9s sous licence par plusieurs distributeurs internationaux ou en attente d\u2019AMM dans plusieurs pays cl\u00e9s.<\/p>\n<p>Onxeo a c\u00e9d\u00e9 \u00e0 Vectans Pharma tous les actifs associ\u00e9s aux deux m\u00e9dicaments (notamment les brevets, autorisations r\u00e9glementaires et contrats en cours), contre un paiement initial de 4 millions d\u2019euros. L&#8217;accord comporte \u00e9galement une clause d&#8217;int\u00e9ressement aux ventes futures sur la base de la performance commerciale cumul\u00e9e des deux produits \u00e0 l&#8217;\u00e9chelle mondiale. Onxeo percevra en outre, de la part de ses partenaires existants, la plupart des paiements attendus au cours des trois prochaines ann\u00e9es li\u00e9es au franchissement d&#8217;\u00e9tapes pr\u00e9d\u00e9finies r\u00e9glementaires ou de performances commerciales.<\/p>\n<p>Cette transaction illustre la transformation strat\u00e9gique d\u2019Onxeo amorc\u00e9e il y a quelques ann\u00e9es, qui ambitionne de devenir un acteur mondial de premier plan et un pionnier dans le domaine des cancers orphelins ou rares.<\/p>\n<p>&nbsp;<\/p>\n<p><strong>Conseils d\u2019Onxeo<\/strong><\/p>\n<p>Altana\u00a0avec Jean-Nicolas Soret (associ\u00e9), Fabien Pouchot (counsel) et Vincent Guilaine.<\/p>\n<p><strong>Conseil de Vectan Pharma<\/strong><\/p>\n<p>Almain avec Edgard Nguyen (associ\u00e9).<\/p>\n<p>&nbsp;<\/p>\n<p><strong>A propos d\u2019Altana<\/strong><\/p>\n<p>Altana est un cabinet d\u2019avocats d\u2019affaires ind\u00e9pendant install\u00e9 \u00e0 Paris, compos\u00e9 de 80 avocats. Les avocats d\u2019Altana sont tr\u00e8s attach\u00e9s \u00e0 la double pratique du conseil et de la r\u00e9solution des litiges au service des entreprises. Ils interviennent dans les domaines suivants :<\/p>\n<p>Arbitrage \/ M\u00e9diation, Assurance, Corporate \/ M&amp;A, Concurrence \/ Distribution, Contentieux, Droit p\u00e9nal, Droit social, Droit public \u00e9conomique, Droit de la construction et de l\u2019immobilier, Propri\u00e9t\u00e9 intellectuelle et num\u00e9rique, Restructuration.<\/p>\n<p>L&#8217;ensemble des 80 avocats dont 22 associ\u00e9s partagent des valeurs communes : vision entrepreneuriale, ind\u00e9pendance, engagement, ouverture internationale, relations p\u00e9rennes et privil\u00e9gi\u00e9es avec leurs clients, intervention effective des associ\u00e9s dans chaque dossier, solutions pragmatiques et innovantes<\/p>\n<p>&nbsp;<\/p>\n<p><strong>Contacts Presse<\/strong><\/p>\n<table>\n<tbody>\n<tr>\n<td width=\"300\"><strong>Avocom<\/strong><\/p>\n<p>Virginie Jubault<\/p>\n<p>v.jubault@avocom.fr<\/p>\n<p>01 48 24 00 41<\/td>\n<td width=\"314\">&nbsp;<\/p>\n<p>Nathalie Merle<\/p>\n<p>n.merle@avocom.fr<\/p>\n<p>01 48 24 00 39<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><strong>\u00a0<\/strong><\/p>","protected":false},"excerpt":{"rendered":"<p>\u7533\u3057\u8a33\u3042\u308a\u307e\u305b\u3093\u3001\u3053\u306e\u30b3\u30f3\u30c6\u30f3\u30c4\u306f\u305f\u3060\u4eca\u3000Fran\u00e7ais\u3068 English\u3000\u306e\u307f\u3067\u3059\u3002 For the sake of viewer convenience, the content is shown below in [&hellip;]<\/p>\n","protected":false},"author":14,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-5072","post","type-post","status-publish","format-standard","hentry","category-medias","expertise-droit-societes-fusions-acquisitions","avocat-fabien-pouchot","avocat-jean-nicolas-soret"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v22.2 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title><\/title>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"ja_JP\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"[:fr]Altana conseille Onxeo dans la cession \u00e0 Vectans Pharma de deux produits non strat\u00e9giques dans les pathologies buccales [:en]Altana Advises Onxeo in the Divestment of Two Non-Core Oral Pathology Products to Vectans Pharma[:] - Altana\" \/>\n<meta property=\"og:description\" content=\"\u7533\u3057\u8a33\u3042\u308a\u307e\u305b\u3093\u3001\u3053\u306e\u30b3\u30f3\u30c6\u30f3\u30c4\u306f\u305f\u3060\u4eca\u3000Fran\u00e7ais\u3068 English\u3000\u306e\u307f\u3067\u3059\u3002 For the sake of viewer convenience, the content is shown below in [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/backup.altanalaw.com\/medias\/altana-conseille-onxeo-dans-la-cession-a-vectans-pharma-de-deux-produits-non-strategiques-dans-les-pathologies-buccales\" \/>\n<meta property=\"og:site_name\" content=\"Altana\" \/>\n<meta property=\"article:published_time\" content=\"2017-08-22T11:17:11+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2017-08-22T11:28:23+00:00\" \/>\n<meta name=\"author\" content=\"Altana Communication\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u57f7\u7b46\u8005\" \/>\n\t<meta name=\"twitter:data1\" content=\"Altana Communication\" \/>\n\t<meta name=\"twitter:label2\" content=\"\u63a8\u5b9a\u8aad\u307f\u53d6\u308a\u6642\u9593\" \/>\n\t<meta name=\"twitter:data2\" content=\"4\u5206\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/backup.altanalaw.com\/medias\/altana-conseille-onxeo-dans-la-cession-a-vectans-pharma-de-deux-produits-non-strategiques-dans-les-pathologies-buccales\",\"url\":\"https:\/\/backup.altanalaw.com\/medias\/altana-conseille-onxeo-dans-la-cession-a-vectans-pharma-de-deux-produits-non-strategiques-dans-les-pathologies-buccales\",\"name\":\"[:fr]Altana conseille Onxeo dans la cession \u00e0 Vectans Pharma de deux produits non strat\u00e9giques dans les pathologies buccales [:en]Altana Advises Onxeo in the Divestment of Two Non-Core Oral Pathology Products to Vectans Pharma[:] - Altana\",\"isPartOf\":{\"@id\":\"https:\/\/backup.altanalaw.com\/#website\"},\"datePublished\":\"2017-08-22T11:17:11+00:00\",\"dateModified\":\"2017-08-22T11:28:23+00:00\",\"author\":{\"@id\":\"https:\/\/backup.altanalaw.com\/#\/schema\/person\/4bdb47072f79b38f30b44735a4377af6\"},\"inLanguage\":\"ja\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/backup.altanalaw.com\/medias\/altana-conseille-onxeo-dans-la-cession-a-vectans-pharma-de-deux-produits-non-strategiques-dans-les-pathologies-buccales\"]}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/backup.altanalaw.com\/#website\",\"url\":\"https:\/\/backup.altanalaw.com\/\",\"name\":\"Altana\",\"description\":\"Soci\u00e9t\u00e9 d&#039;avocats \u00e0 la Cour de Paris\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/backup.altanalaw.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"ja\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/backup.altanalaw.com\/#\/schema\/person\/4bdb47072f79b38f30b44735a4377af6\",\"name\":\"Altana Communication\",\"url\":\"https:\/\/backup.altanalaw.com\/ja\/author\/altanacomm\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"[:fr]Altana conseille Onxeo dans la cession \u00e0 Vectans Pharma de deux produits non strat\u00e9giques dans les pathologies buccales [:en]Altana Advises Onxeo in the Divestment of Two Non-Core Oral Pathology Products to Vectans Pharma[:] - Altana","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"ja_JP","og_type":"article","og_title":"[:fr]Altana conseille Onxeo dans la cession \u00e0 Vectans Pharma de deux produits non strat\u00e9giques dans les pathologies buccales [:en]Altana Advises Onxeo in the Divestment of Two Non-Core Oral Pathology Products to Vectans Pharma[:] - Altana","og_description":"\u7533\u3057\u8a33\u3042\u308a\u307e\u305b\u3093\u3001\u3053\u306e\u30b3\u30f3\u30c6\u30f3\u30c4\u306f\u305f\u3060\u4eca\u3000Fran\u00e7ais\u3068 English\u3000\u306e\u307f\u3067\u3059\u3002 For the sake of viewer convenience, the content is shown below in [&hellip;]","og_url":"https:\/\/backup.altanalaw.com\/medias\/altana-conseille-onxeo-dans-la-cession-a-vectans-pharma-de-deux-produits-non-strategiques-dans-les-pathologies-buccales","og_site_name":"Altana","article_published_time":"2017-08-22T11:17:11+00:00","article_modified_time":"2017-08-22T11:28:23+00:00","author":"Altana Communication","twitter_card":"summary_large_image","twitter_misc":{"\u57f7\u7b46\u8005":"Altana Communication","\u63a8\u5b9a\u8aad\u307f\u53d6\u308a\u6642\u9593":"4\u5206"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/backup.altanalaw.com\/medias\/altana-conseille-onxeo-dans-la-cession-a-vectans-pharma-de-deux-produits-non-strategiques-dans-les-pathologies-buccales","url":"https:\/\/backup.altanalaw.com\/medias\/altana-conseille-onxeo-dans-la-cession-a-vectans-pharma-de-deux-produits-non-strategiques-dans-les-pathologies-buccales","name":"[:fr]Altana conseille Onxeo dans la cession \u00e0 Vectans Pharma de deux produits non strat\u00e9giques dans les pathologies buccales [:en]Altana Advises Onxeo in the Divestment of Two Non-Core Oral Pathology Products to Vectans Pharma[:] - Altana","isPartOf":{"@id":"https:\/\/backup.altanalaw.com\/#website"},"datePublished":"2017-08-22T11:17:11+00:00","dateModified":"2017-08-22T11:28:23+00:00","author":{"@id":"https:\/\/backup.altanalaw.com\/#\/schema\/person\/4bdb47072f79b38f30b44735a4377af6"},"inLanguage":"ja","potentialAction":[{"@type":"ReadAction","target":["https:\/\/backup.altanalaw.com\/medias\/altana-conseille-onxeo-dans-la-cession-a-vectans-pharma-de-deux-produits-non-strategiques-dans-les-pathologies-buccales"]}]},{"@type":"WebSite","@id":"https:\/\/backup.altanalaw.com\/#website","url":"https:\/\/backup.altanalaw.com\/","name":"Altana","description":"Soci\u00e9t\u00e9 d&#039;avocats \u00e0 la Cour de Paris","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/backup.altanalaw.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"ja"},{"@type":"Person","@id":"https:\/\/backup.altanalaw.com\/#\/schema\/person\/4bdb47072f79b38f30b44735a4377af6","name":"Altana Communication","url":"https:\/\/backup.altanalaw.com\/ja\/author\/altanacomm"}]}},"_links":{"self":[{"href":"https:\/\/backup.altanalaw.com\/ja\/wp-json\/wp\/v2\/posts\/5072"}],"collection":[{"href":"https:\/\/backup.altanalaw.com\/ja\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/backup.altanalaw.com\/ja\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/backup.altanalaw.com\/ja\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/backup.altanalaw.com\/ja\/wp-json\/wp\/v2\/comments?post=5072"}],"version-history":[{"count":7,"href":"https:\/\/backup.altanalaw.com\/ja\/wp-json\/wp\/v2\/posts\/5072\/revisions"}],"predecessor-version":[{"id":5082,"href":"https:\/\/backup.altanalaw.com\/ja\/wp-json\/wp\/v2\/posts\/5072\/revisions\/5082"}],"wp:attachment":[{"href":"https:\/\/backup.altanalaw.com\/ja\/wp-json\/wp\/v2\/media?parent=5072"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/backup.altanalaw.com\/ja\/wp-json\/wp\/v2\/categories?post=5072"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/backup.altanalaw.com\/ja\/wp-json\/wp\/v2\/tags?post=5072"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}